XOMA Royalty (XOMA) Stock Overview
Operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
XOMA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
XOMA Royalty Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$39.61 |
| 52 Week High | US$40.70 |
| 52 Week Low | US$20.59 |
| Beta | 0.68 |
| 1 Month Change | 46.70% |
| 3 Month Change | 50.21% |
| 1 Year Change | 87.02% |
| 3 Year Change | 111.71% |
| 5 Year Change | 7.93% |
| Change since IPO | -99.17% |
Recent News & Updates
Expanding Royalty Portfolio And Funded Pipelines Will Reshape Long Term Earnings Quality
Catalysts About XOMA Royalty XOMA Royalty builds and manages a diversified portfolio of biotechnology royalty and milestone interests across the drug development cycle. What are the underlying business or industry changes driving this perspective?
Future Royalty Concentration And Litigation Risks May Eventually Reward Patient Holders
Catalysts About XOMA Royalty XOMA Royalty aggregates biotechnology royalty and milestone interests across the drug development spectrum, aiming to build a diversified, cash generative portfolio funded largely by third party R&D spend. What are the underlying business or industry changes driving this perspective?Recent updates
Expanding Royalty Portfolio And Funded Pipelines Will Reshape Long Term Earnings Quality
Catalysts About XOMA Royalty XOMA Royalty builds and manages a diversified portfolio of biotechnology royalty and milestone interests across the drug development cycle. What are the underlying business or industry changes driving this perspective?Future Royalty Concentration And Litigation Risks May Eventually Reward Patient Holders
Catalysts About XOMA Royalty XOMA Royalty aggregates biotechnology royalty and milestone interests across the drug development spectrum, aiming to build a diversified, cash generative portfolio funded largely by third party R&D spend. What are the underlying business or industry changes driving this perspective?Investors Don't See Light At End Of XOMA Royalty Corporation's (NASDAQ:XOMA) Tunnel
Dec 15
XOMA Royalty PFD Update: Going Back To My Original Sell Ratings
Oct 03XOMA Royalty Corporation's (NASDAQ:XOMA) Shares Climb 27% But Its Business Is Yet to Catch Up
Aug 21XOMA Royalty Corporation's (NASDAQ:XOMA) 27% Share Price Surge Not Quite Adding Up
May 08XOMA Royalty (NASDAQ:XOMA) Is Making Moderate Use Of Debt
Apr 16Risks Still Elevated At These Prices As XOMA Royalty Corporation (NASDAQ:XOMA) Shares Dive 25%
Mar 14XOMA Royalty's Preferred Shares: High-Yield Dividends From Biotech Royalties
Oct 15News Flash: Analysts Just Made A Notable Upgrade To Their XOMA Royalty Corporation (NASDAQ:XOMA) Forecasts
Aug 14Health Check: How Prudently Does XOMA Royalty (NASDAQ:XOMA) Use Debt?
Aug 02XOMA Corporation: A Hold Rating With Steady Income From Preferred Shares
Jun 29Is XOMA (NASDAQ:XOMA) Using Debt Sensibly?
Apr 03Are Investors Undervaluing XOMA Corporation (NASDAQ:XOMA) By 49%?
Sep 01Bearish: Analysts Just Cut Their XOMA Corporation (NASDAQ:XOMA) Revenue and EPS estimates
Aug 11XOMA GAAP EPS of -$0.53 misses by $0.37, revenue of $0.98M misses by $3.29M
Aug 04Forecast: Analysts Think XOMA Corporation's (NASDAQ:XOMA) Business Prospects Have Improved Drastically
May 08Xoma Gets The Spotlight
Sep 02Things Look Grim For XOMA Corporation (NASDAQ:XOMA) After Today's Downgrade
Aug 20We Think The Compensation For XOMA Corporation's (NASDAQ:XOMA) CEO Looks About Right
May 13Does XOMA (NASDAQ:XOMA) Have A Healthy Balance Sheet?
May 11XOMA's (NASDAQ:XOMA) Earnings Are Of Questionable Quality
Mar 17Analysts Are More Bearish On XOMA Corporation (NASDAQ:XOMA) Than They Used To Be
Mar 16Is XOMA Corporation (NASDAQ:XOMA) Popular Amongst Institutions?
Mar 09Did You Miss XOMA's (NASDAQ:XOMA) Impressive 140% Share Price Gain?
Feb 02
Shareholder Returns
| XOMA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 7.8% | 2.0% | 3.4% |
| 1Y | 87.0% | 43.3% | 34.6% |
Return vs Industry: XOMA exceeded the US Biotechs industry which returned 43.3% over the past year.
Return vs Market: XOMA exceeded the US Market which returned 34.6% over the past year.
Price Volatility
| XOMA volatility | |
|---|---|
| XOMA Average Weekly Movement | 6.5% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: XOMA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: XOMA's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 14 | Owen Hughes | www.xoma.com |
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to sponsors or developers; and acquires milestone and royalty revenue streams on late-stage clinical assets and commercial assets.
XOMA Royalty Corporation Fundamentals Summary
| XOMA fundamental statistics | |
|---|---|
| Market cap | US$478.18m |
| Earnings (TTM) | US$18.52m |
| Revenue (TTM) | US$52.15m |
Is XOMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XOMA income statement (TTM) | |
|---|---|
| Revenue | US$52.15m |
| Cost of Revenue | US$1.71m |
| Gross Profit | US$50.44m |
| Other Expenses | US$31.92m |
| Earnings | US$18.52m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.55 |
| Gross Margin | 96.72% |
| Net Profit Margin | 35.51% |
| Debt/Equity Ratio | 104.8% |
How did XOMA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/16 22:41 |
| End of Day Share Price | 2026/04/16 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
XOMA Royalty Corporation is covered by 13 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert Wasserman | Benchmark Company |
| Ritu Baral | Canaccord Genuity |
| Joseph Pantginis | H.C. Wainwright & Co. |